Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin
Purpose: Hepatitis B virus infection is a well-known risk factor for intrahepatic cholangiocarcinoma. However, its prognostic impact has rarely been investigated in advanced intrahepatic cholangiocarcinoma. Methods: Between April 2010 and May 2015, 296 patients with unresectable or metastatic intrah...
Gespeichert in:
| Veröffentlicht in: | The International journal of biological markers 2018-11, Vol.33 (4), p.432-438 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 438 |
|---|---|
| container_issue | 4 |
| container_start_page | 432 |
| container_title | The International journal of biological markers |
| container_volume | 33 |
| creator | Chae, Heejung Cho, Hyungwoo Yoo, Changhoon Kim, Kyu-pyo Jeong, Jae Ho Chang, Heung-Moon Kang, Jihoon Lee, Han Chu Lim, Young-Suk Kim, Kang Mo Shim, Ju Hyun Lee, Sang Soo Park, Do Hyun Song, Tae Jun Hwang, Shin Song, Gi-Won Moon, Deok-Bog Lee, Young-Joo Lee, Jae Hoon Ryoo, Baek-Yeol |
| description | Purpose:
Hepatitis B virus infection is a well-known risk factor for intrahepatic cholangiocarcinoma. However, its prognostic impact has rarely been investigated in advanced intrahepatic cholangiocarcinoma.
Methods:
Between April 2010 and May 2015, 296 patients with unresectable or metastatic intrahepatic cholangiocarcinoma who received gemcitabine plus cisplatin (GemCis) were categorized into a hepatitis B virus group (n=62; 21%) and a non-hepatitis B virus group (n=234; 79%). Clinicopathological features and survival outcomes were retrospectively reviewed and analyzed.
Results:
The median age of patients was 59 years (range, 27–78). The median overall survival with first-line GemCis was 9.4 months (95% CI 8.4, 10.4). Compared to the non-hepatitis B virus group, the hepatitis B virus group was younger (median age, 57 vs. 61 years, P = 0.001), mainly male (74% vs. 57%, P = 0.02), and had lower frequency of elevated cancer antigen (CA) 19-9 (34% vs. 59%, P = 0.001) and alkaline phosphatase (43% vs. 61%, P = 0.01). In a univariate analysis, the hepatitis B virus infection showed a marginal relationship with poor overall survival compared to the non-hepatitis B virus infection (median, 8.3 vs. 10.0 months; P=0.13). A multivariate analysis of potential prognostic factors revealed a significant association with poor overall survival in the hepatitis B virus group (hazard ratio (HR) =1.50, P = 0.02). Initial metastatic disease (vs. recurrent/unresectable disease; HR=1.50), metastatic sites ⩾ 2 (vs. 0–1; HR=1.51), Eastern Cooperative Oncology Group performance status ⩾ 2 (vs. 0–1; HR=1.93), elevated total bilirubin (vs. normal; HR=1.83), and low albumin (vs. normal; HR=1.52) were significantly related to an unfavorable overall survival.
Conclusions:
This study suggests that the hepatitis B virus infection may be associated with distinctive clinicopathological characteristics and poor outcome in advanced intrahepatic cholangiocarcinoma treated with GemCis. |
| doi_str_mv | 10.1177/1724600818777239 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_2051669641</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1724600818777239</sage_id><sourcerecordid>2051669641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c407t-49901562320adecb20d968cabc24a3ad91e0f6f1227f68dfe6856620f2d7d70d3</originalsourceid><addsrcrecordid>eNp1kUtLAzEUhYMotlb3riTgxs1okpkmk6UWX1DQha6HNI82ZWYyJhnF_-CPNkPrA0EI5Nyb754kHACOMTrHmLELzEhBESpxyRgjOd8B46GVDb3dX3oEDkJYI0QwYnQfjAgvWcHL6Rh8PHq3bF2IVkLbdLWVIlrXBugMXOkuFdEGeAVfre8DtK3RcjhPKq3oxYaRUK5cLdqldVJ4aVvXCBi9FlEr-GbjChrrQ8xq22q41I20USwG3dXJVdrQ1cmlPQR7RtRBH233CXi-uX6a3WXzh9v72eU8kwViMSs4R3hKSU6QUFouCFKcllIsJClELhTHGhlqMCHM0FIZTcsppQQZophiSOUTcLbx7bx76XWIVWOD1HX6gXZ9qAiaYko5LXBCT_-ga9f7Nr2uIjnOGaOMs0ShDSW9C8FrU3XeNsK_VxhVQ1LV36TSyMnWuF80Wn0PfEWTgGwDBLHUP7f-a_gJrmCd6Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2313776797</pqid></control><display><type>article</type><title>Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin</title><source>Sage Journals GOLD Open Access 2024</source><creator>Chae, Heejung ; Cho, Hyungwoo ; Yoo, Changhoon ; Kim, Kyu-pyo ; Jeong, Jae Ho ; Chang, Heung-Moon ; Kang, Jihoon ; Lee, Han Chu ; Lim, Young-Suk ; Kim, Kang Mo ; Shim, Ju Hyun ; Lee, Sang Soo ; Park, Do Hyun ; Song, Tae Jun ; Hwang, Shin ; Song, Gi-Won ; Moon, Deok-Bog ; Lee, Young-Joo ; Lee, Jae Hoon ; Ryoo, Baek-Yeol</creator><creatorcontrib>Chae, Heejung ; Cho, Hyungwoo ; Yoo, Changhoon ; Kim, Kyu-pyo ; Jeong, Jae Ho ; Chang, Heung-Moon ; Kang, Jihoon ; Lee, Han Chu ; Lim, Young-Suk ; Kim, Kang Mo ; Shim, Ju Hyun ; Lee, Sang Soo ; Park, Do Hyun ; Song, Tae Jun ; Hwang, Shin ; Song, Gi-Won ; Moon, Deok-Bog ; Lee, Young-Joo ; Lee, Jae Hoon ; Ryoo, Baek-Yeol</creatorcontrib><description>Purpose:
Hepatitis B virus infection is a well-known risk factor for intrahepatic cholangiocarcinoma. However, its prognostic impact has rarely been investigated in advanced intrahepatic cholangiocarcinoma.
Methods:
Between April 2010 and May 2015, 296 patients with unresectable or metastatic intrahepatic cholangiocarcinoma who received gemcitabine plus cisplatin (GemCis) were categorized into a hepatitis B virus group (n=62; 21%) and a non-hepatitis B virus group (n=234; 79%). Clinicopathological features and survival outcomes were retrospectively reviewed and analyzed.
Results:
The median age of patients was 59 years (range, 27–78). The median overall survival with first-line GemCis was 9.4 months (95% CI 8.4, 10.4). Compared to the non-hepatitis B virus group, the hepatitis B virus group was younger (median age, 57 vs. 61 years, P = 0.001), mainly male (74% vs. 57%, P = 0.02), and had lower frequency of elevated cancer antigen (CA) 19-9 (34% vs. 59%, P = 0.001) and alkaline phosphatase (43% vs. 61%, P = 0.01). In a univariate analysis, the hepatitis B virus infection showed a marginal relationship with poor overall survival compared to the non-hepatitis B virus infection (median, 8.3 vs. 10.0 months; P=0.13). A multivariate analysis of potential prognostic factors revealed a significant association with poor overall survival in the hepatitis B virus group (hazard ratio (HR) =1.50, P = 0.02). Initial metastatic disease (vs. recurrent/unresectable disease; HR=1.50), metastatic sites ⩾ 2 (vs. 0–1; HR=1.51), Eastern Cooperative Oncology Group performance status ⩾ 2 (vs. 0–1; HR=1.93), elevated total bilirubin (vs. normal; HR=1.83), and low albumin (vs. normal; HR=1.52) were significantly related to an unfavorable overall survival.
Conclusions:
This study suggests that the hepatitis B virus infection may be associated with distinctive clinicopathological characteristics and poor outcome in advanced intrahepatic cholangiocarcinoma treated with GemCis.</description><identifier>ISSN: 1724-6008</identifier><identifier>ISSN: 0393-6155</identifier><identifier>EISSN: 1724-6008</identifier><identifier>DOI: 10.1177/1724600818777239</identifier><identifier>PMID: 29874985</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Aged ; Alkaline phosphatase ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bile Duct Neoplasms - drug therapy ; Bile Duct Neoplasms - mortality ; Bile Duct Neoplasms - pathology ; Bilirubin ; Bilirubin - analysis ; Chemotherapy ; Cholangiocarcinoma ; Cholangiocarcinoma - drug therapy ; Cholangiocarcinoma - mortality ; Cholangiocarcinoma - pathology ; Cisplatin ; Cisplatin - administration & dosage ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Female ; Gemcitabine ; Hepatitis ; Hepatitis B ; Hepatitis B - complications ; Humans ; Infections ; Male ; Medical prognosis ; Metastases ; Metastasis ; Middle Aged ; Multivariate analysis ; Oncology ; Prognosis ; Retrospective Studies ; Risk factors ; Survival</subject><ispartof>The International journal of biological markers, 2018-11, Vol.33 (4), p.432-438</ispartof><rights>The Author(s) 2018</rights><rights>The Author(s) 2018. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c407t-49901562320adecb20d968cabc24a3ad91e0f6f1227f68dfe6856620f2d7d70d3</citedby><cites>FETCH-LOGICAL-c407t-49901562320adecb20d968cabc24a3ad91e0f6f1227f68dfe6856620f2d7d70d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1724600818777239$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1724600818777239$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21966,27853,27924,27925,44945,45333</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/1724600818777239?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29874985$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chae, Heejung</creatorcontrib><creatorcontrib>Cho, Hyungwoo</creatorcontrib><creatorcontrib>Yoo, Changhoon</creatorcontrib><creatorcontrib>Kim, Kyu-pyo</creatorcontrib><creatorcontrib>Jeong, Jae Ho</creatorcontrib><creatorcontrib>Chang, Heung-Moon</creatorcontrib><creatorcontrib>Kang, Jihoon</creatorcontrib><creatorcontrib>Lee, Han Chu</creatorcontrib><creatorcontrib>Lim, Young-Suk</creatorcontrib><creatorcontrib>Kim, Kang Mo</creatorcontrib><creatorcontrib>Shim, Ju Hyun</creatorcontrib><creatorcontrib>Lee, Sang Soo</creatorcontrib><creatorcontrib>Park, Do Hyun</creatorcontrib><creatorcontrib>Song, Tae Jun</creatorcontrib><creatorcontrib>Hwang, Shin</creatorcontrib><creatorcontrib>Song, Gi-Won</creatorcontrib><creatorcontrib>Moon, Deok-Bog</creatorcontrib><creatorcontrib>Lee, Young-Joo</creatorcontrib><creatorcontrib>Lee, Jae Hoon</creatorcontrib><creatorcontrib>Ryoo, Baek-Yeol</creatorcontrib><title>Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin</title><title>The International journal of biological markers</title><addtitle>Int J Biol Markers</addtitle><description>Purpose:
Hepatitis B virus infection is a well-known risk factor for intrahepatic cholangiocarcinoma. However, its prognostic impact has rarely been investigated in advanced intrahepatic cholangiocarcinoma.
Methods:
Between April 2010 and May 2015, 296 patients with unresectable or metastatic intrahepatic cholangiocarcinoma who received gemcitabine plus cisplatin (GemCis) were categorized into a hepatitis B virus group (n=62; 21%) and a non-hepatitis B virus group (n=234; 79%). Clinicopathological features and survival outcomes were retrospectively reviewed and analyzed.
Results:
The median age of patients was 59 years (range, 27–78). The median overall survival with first-line GemCis was 9.4 months (95% CI 8.4, 10.4). Compared to the non-hepatitis B virus group, the hepatitis B virus group was younger (median age, 57 vs. 61 years, P = 0.001), mainly male (74% vs. 57%, P = 0.02), and had lower frequency of elevated cancer antigen (CA) 19-9 (34% vs. 59%, P = 0.001) and alkaline phosphatase (43% vs. 61%, P = 0.01). In a univariate analysis, the hepatitis B virus infection showed a marginal relationship with poor overall survival compared to the non-hepatitis B virus infection (median, 8.3 vs. 10.0 months; P=0.13). A multivariate analysis of potential prognostic factors revealed a significant association with poor overall survival in the hepatitis B virus group (hazard ratio (HR) =1.50, P = 0.02). Initial metastatic disease (vs. recurrent/unresectable disease; HR=1.50), metastatic sites ⩾ 2 (vs. 0–1; HR=1.51), Eastern Cooperative Oncology Group performance status ⩾ 2 (vs. 0–1; HR=1.93), elevated total bilirubin (vs. normal; HR=1.83), and low albumin (vs. normal; HR=1.52) were significantly related to an unfavorable overall survival.
Conclusions:
This study suggests that the hepatitis B virus infection may be associated with distinctive clinicopathological characteristics and poor outcome in advanced intrahepatic cholangiocarcinoma treated with GemCis.</description><subject>Adult</subject><subject>Aged</subject><subject>Alkaline phosphatase</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bile Duct Neoplasms - drug therapy</subject><subject>Bile Duct Neoplasms - mortality</subject><subject>Bile Duct Neoplasms - pathology</subject><subject>Bilirubin</subject><subject>Bilirubin - analysis</subject><subject>Chemotherapy</subject><subject>Cholangiocarcinoma</subject><subject>Cholangiocarcinoma - drug therapy</subject><subject>Cholangiocarcinoma - mortality</subject><subject>Cholangiocarcinoma - pathology</subject><subject>Cisplatin</subject><subject>Cisplatin - administration & dosage</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Female</subject><subject>Gemcitabine</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B - complications</subject><subject>Humans</subject><subject>Infections</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Survival</subject><issn>1724-6008</issn><issn>0393-6155</issn><issn>1724-6008</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kUtLAzEUhYMotlb3riTgxs1okpkmk6UWX1DQha6HNI82ZWYyJhnF_-CPNkPrA0EI5Nyb754kHACOMTrHmLELzEhBESpxyRgjOd8B46GVDb3dX3oEDkJYI0QwYnQfjAgvWcHL6Rh8PHq3bF2IVkLbdLWVIlrXBugMXOkuFdEGeAVfre8DtK3RcjhPKq3oxYaRUK5cLdqldVJ4aVvXCBi9FlEr-GbjChrrQ8xq22q41I20USwG3dXJVdrQ1cmlPQR7RtRBH233CXi-uX6a3WXzh9v72eU8kwViMSs4R3hKSU6QUFouCFKcllIsJClELhTHGhlqMCHM0FIZTcsppQQZophiSOUTcLbx7bx76XWIVWOD1HX6gXZ9qAiaYko5LXBCT_-ga9f7Nr2uIjnOGaOMs0ShDSW9C8FrU3XeNsK_VxhVQ1LV36TSyMnWuF80Wn0PfEWTgGwDBLHUP7f-a_gJrmCd6Q</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Chae, Heejung</creator><creator>Cho, Hyungwoo</creator><creator>Yoo, Changhoon</creator><creator>Kim, Kyu-pyo</creator><creator>Jeong, Jae Ho</creator><creator>Chang, Heung-Moon</creator><creator>Kang, Jihoon</creator><creator>Lee, Han Chu</creator><creator>Lim, Young-Suk</creator><creator>Kim, Kang Mo</creator><creator>Shim, Ju Hyun</creator><creator>Lee, Sang Soo</creator><creator>Park, Do Hyun</creator><creator>Song, Tae Jun</creator><creator>Hwang, Shin</creator><creator>Song, Gi-Won</creator><creator>Moon, Deok-Bog</creator><creator>Lee, Young-Joo</creator><creator>Lee, Jae Hoon</creator><creator>Ryoo, Baek-Yeol</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>KB0</scope><scope>LK8</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201811</creationdate><title>Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin</title><author>Chae, Heejung ; Cho, Hyungwoo ; Yoo, Changhoon ; Kim, Kyu-pyo ; Jeong, Jae Ho ; Chang, Heung-Moon ; Kang, Jihoon ; Lee, Han Chu ; Lim, Young-Suk ; Kim, Kang Mo ; Shim, Ju Hyun ; Lee, Sang Soo ; Park, Do Hyun ; Song, Tae Jun ; Hwang, Shin ; Song, Gi-Won ; Moon, Deok-Bog ; Lee, Young-Joo ; Lee, Jae Hoon ; Ryoo, Baek-Yeol</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c407t-49901562320adecb20d968cabc24a3ad91e0f6f1227f68dfe6856620f2d7d70d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alkaline phosphatase</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bile Duct Neoplasms - drug therapy</topic><topic>Bile Duct Neoplasms - mortality</topic><topic>Bile Duct Neoplasms - pathology</topic><topic>Bilirubin</topic><topic>Bilirubin - analysis</topic><topic>Chemotherapy</topic><topic>Cholangiocarcinoma</topic><topic>Cholangiocarcinoma - drug therapy</topic><topic>Cholangiocarcinoma - mortality</topic><topic>Cholangiocarcinoma - pathology</topic><topic>Cisplatin</topic><topic>Cisplatin - administration & dosage</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Female</topic><topic>Gemcitabine</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B - complications</topic><topic>Humans</topic><topic>Infections</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chae, Heejung</creatorcontrib><creatorcontrib>Cho, Hyungwoo</creatorcontrib><creatorcontrib>Yoo, Changhoon</creatorcontrib><creatorcontrib>Kim, Kyu-pyo</creatorcontrib><creatorcontrib>Jeong, Jae Ho</creatorcontrib><creatorcontrib>Chang, Heung-Moon</creatorcontrib><creatorcontrib>Kang, Jihoon</creatorcontrib><creatorcontrib>Lee, Han Chu</creatorcontrib><creatorcontrib>Lim, Young-Suk</creatorcontrib><creatorcontrib>Kim, Kang Mo</creatorcontrib><creatorcontrib>Shim, Ju Hyun</creatorcontrib><creatorcontrib>Lee, Sang Soo</creatorcontrib><creatorcontrib>Park, Do Hyun</creatorcontrib><creatorcontrib>Song, Tae Jun</creatorcontrib><creatorcontrib>Hwang, Shin</creatorcontrib><creatorcontrib>Song, Gi-Won</creatorcontrib><creatorcontrib>Moon, Deok-Bog</creatorcontrib><creatorcontrib>Lee, Young-Joo</creatorcontrib><creatorcontrib>Lee, Jae Hoon</creatorcontrib><creatorcontrib>Ryoo, Baek-Yeol</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>The International journal of biological markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Chae, Heejung</au><au>Cho, Hyungwoo</au><au>Yoo, Changhoon</au><au>Kim, Kyu-pyo</au><au>Jeong, Jae Ho</au><au>Chang, Heung-Moon</au><au>Kang, Jihoon</au><au>Lee, Han Chu</au><au>Lim, Young-Suk</au><au>Kim, Kang Mo</au><au>Shim, Ju Hyun</au><au>Lee, Sang Soo</au><au>Park, Do Hyun</au><au>Song, Tae Jun</au><au>Hwang, Shin</au><au>Song, Gi-Won</au><au>Moon, Deok-Bog</au><au>Lee, Young-Joo</au><au>Lee, Jae Hoon</au><au>Ryoo, Baek-Yeol</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin</atitle><jtitle>The International journal of biological markers</jtitle><addtitle>Int J Biol Markers</addtitle><date>2018-11</date><risdate>2018</risdate><volume>33</volume><issue>4</issue><spage>432</spage><epage>438</epage><pages>432-438</pages><issn>1724-6008</issn><issn>0393-6155</issn><eissn>1724-6008</eissn><abstract>Purpose:
Hepatitis B virus infection is a well-known risk factor for intrahepatic cholangiocarcinoma. However, its prognostic impact has rarely been investigated in advanced intrahepatic cholangiocarcinoma.
Methods:
Between April 2010 and May 2015, 296 patients with unresectable or metastatic intrahepatic cholangiocarcinoma who received gemcitabine plus cisplatin (GemCis) were categorized into a hepatitis B virus group (n=62; 21%) and a non-hepatitis B virus group (n=234; 79%). Clinicopathological features and survival outcomes were retrospectively reviewed and analyzed.
Results:
The median age of patients was 59 years (range, 27–78). The median overall survival with first-line GemCis was 9.4 months (95% CI 8.4, 10.4). Compared to the non-hepatitis B virus group, the hepatitis B virus group was younger (median age, 57 vs. 61 years, P = 0.001), mainly male (74% vs. 57%, P = 0.02), and had lower frequency of elevated cancer antigen (CA) 19-9 (34% vs. 59%, P = 0.001) and alkaline phosphatase (43% vs. 61%, P = 0.01). In a univariate analysis, the hepatitis B virus infection showed a marginal relationship with poor overall survival compared to the non-hepatitis B virus infection (median, 8.3 vs. 10.0 months; P=0.13). A multivariate analysis of potential prognostic factors revealed a significant association with poor overall survival in the hepatitis B virus group (hazard ratio (HR) =1.50, P = 0.02). Initial metastatic disease (vs. recurrent/unresectable disease; HR=1.50), metastatic sites ⩾ 2 (vs. 0–1; HR=1.51), Eastern Cooperative Oncology Group performance status ⩾ 2 (vs. 0–1; HR=1.93), elevated total bilirubin (vs. normal; HR=1.83), and low albumin (vs. normal; HR=1.52) were significantly related to an unfavorable overall survival.
Conclusions:
This study suggests that the hepatitis B virus infection may be associated with distinctive clinicopathological characteristics and poor outcome in advanced intrahepatic cholangiocarcinoma treated with GemCis.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>29874985</pmid><doi>10.1177/1724600818777239</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1724-6008 |
| ispartof | The International journal of biological markers, 2018-11, Vol.33 (4), p.432-438 |
| issn | 1724-6008 0393-6155 1724-6008 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2051669641 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Adult Aged Alkaline phosphatase Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bile Duct Neoplasms - drug therapy Bile Duct Neoplasms - mortality Bile Duct Neoplasms - pathology Bilirubin Bilirubin - analysis Chemotherapy Cholangiocarcinoma Cholangiocarcinoma - drug therapy Cholangiocarcinoma - mortality Cholangiocarcinoma - pathology Cisplatin Cisplatin - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Female Gemcitabine Hepatitis Hepatitis B Hepatitis B - complications Humans Infections Male Medical prognosis Metastases Metastasis Middle Aged Multivariate analysis Oncology Prognosis Retrospective Studies Risk factors Survival |
| title | Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A23%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20implications%20of%20hepatitis%20B%20virus%20infection%20in%20intrahepatic%20cholangiocarcinoma%20treated%20with%20first-line%20gemcitabine%20plus%20cisplatin&rft.jtitle=The%20International%20journal%20of%20biological%20markers&rft.au=Chae,%20Heejung&rft.date=2018-11&rft.volume=33&rft.issue=4&rft.spage=432&rft.epage=438&rft.pages=432-438&rft.issn=1724-6008&rft.eissn=1724-6008&rft_id=info:doi/10.1177/1724600818777239&rft_dat=%3Cproquest_AFRWT%3E2051669641%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2313776797&rft_id=info:pmid/29874985&rft_sage_id=10.1177_1724600818777239&rfr_iscdi=true |